Financings

Biomet Inc. completed its private offering of $1 billion of senior notes at an issue price of 6.5 percent.

Celgene Corp. priced two series of senior notes for an aggregate principal amount of $1.5 billion.

Isis Pharmaceuticals Inc. priced an offering of $201.25 million in convertible senior notes, due 2019.

Rosetta Genomics Ltd. closed its public offering of 5.5 million shares at $5 per share.

Atterocor Inc. closed a $16 million Series A round to support a development program in adrenal cancer.

Corcept Therapeutics Inc. sold a royalty on future sales of Korlym for $30 million.

Infinity Pharmaceuticals Inc. plans to raise $76.85 million through a public offering.

Deals

GlaxoSmithKline plc completed its acquisition of Human Genome Sciences Inc. for $3.6 billion.

Capstone Therapeutics Corp. and LipimetiX LLC formed a JV to develop cholesterol lowering drugs.

Islet Sciences Inc. partnered with Spring Point Project for trials of islet cell transplantation for diabetes.

Synthetic Biologics Inc. and Intrexon Corp. partnered to develop MAbs for infectious diseases.

. . . And More

Regeneron Inc.'s Zaltrap (ziv-aflibercept) won FDA approval in metastatic colorectal cancer.

K-V Pharmaceutical Co. filed for Chapter 11 bankruptcy protection.

Astellas Pharma Inc. will close its subsidiary Urogenix Inc. that was acquired in 2006.